# Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant

> **NCT05984199** · PHASE1,PHASE2 · TERMINATED · sponsor: **Vor Biopharma** · enrollment: 38 (actual)

## Conditions studied

- Leukemia, Myeloid, Acute

## Interventions

- **BIOLOGICAL:** VCAR33

## Key facts

- **NCT ID:** NCT05984199
- **Lead sponsor:** Vor Biopharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-12-11
- **Primary completion:** 2025-05-28
- **Final completion:** 2025-05-28
- **Target enrollment:** 38 (ACTUAL)
- **Why stopped:** Lack of Funding
- **Last updated:** 2025-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05984199

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05984199, "Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05984199. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*